BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Vormatrigine readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Vormatrigine\, from ClinicalTrials.gov es
 timates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07505004-8949@assetmemo.bio
DTSTAMP:20261121T005618Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Vormatrigine: Phase 3 readout est. (NCT07505004)
DESCRIPTION:Vormatrigine\, phase 3\, Epilepsy.\nStudy: Randomized Clinical 
 Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults With Fo
 cal Seizures\nEstimated primary completion: January 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/vormatrigine#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07505004
URL:https://assetmemo.bio/drug/vormatrigine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07287163-8949@assetmemo.bio
DTSTAMP:20261121T005618Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Vormatrigine: Phase 3 readout est. (NCT07287163)
DESCRIPTION:Vormatrigine\, phase 3\, Epilepsy.\nStudy: Clinical Trial of Vo
 rmatrigine in Adult Patients With Epilepsy\nEstimated primary completion: 
 31 May 2028. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/vormatri
 gine#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07287163
URL:https://assetmemo.bio/drug/vormatrigine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
